Discover open access scientific publications

Search, annotate, share and cite publications

Publications by B. Han

P1.01-29 Crizotinib in Advanced Lung Adenocarcinoma Patients With ALK or ROS-1 Rearrangement: Is It the Same?

Journal of Thoracic Oncology

English

P1.01-108 Management of Anlotinib-Related Adverse Events: Data From ALTER 0303

Journal of Thoracic Oncology

English

P2.01-01 the Impact of Anlotinib on Brain Metastases of NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)

Journal of Thoracic Oncology

English

JCSE01.21 Different Responses to Osimertinib in Primary and Acquired EGFR T790m-Mutant NSCLC Patients

Journal of Thoracic Oncology

English

P1.01-107 the Impact of Anlotinib on Quality of Life in Patients With Advance NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)

Journal of Thoracic Oncology

English

P3.13-09 ALTER-0303 Study: Tumor Mutation Index (TMI) for Clinical Response to Anlotinib in Advanced NSCLC Patients at 3rd Line

Journal of Thoracic Oncology

English

P1.01-30 Crizotinib in Advanced Non-Adenocarcinoma, NSCLC (NA-NSCLC) Patients With ALK Rearrangement: A Retrospective Study and Literature Review

Journal of Thoracic Oncology

English

P1.11-19 Expression of TNFRII in Serum Is Correlated With the Significant Risk of Subcentimeter Lung Adenocarcinoma

Journal of Thoracic Oncology

English

P2.03-22 OCT4andSOX2 Specific CTLs Plus PD-1 Inhibitor Had Synergistic Effect on Killing CSC and Treating Drug-Resistant Lung Cancer Mice

Journal of Thoracic Oncology

English

JCSE01.19 ALTER-0303 Study: Tumor Mutation Index (TMI) for Clinical Response to Anlotinib in Advanced NSCLC Patients at 3rd Line

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by B. Han

P1.01-29 Crizotinib in Advanced Lung Adenocarcinoma Patients With ALK or ROS-1 Rearrangement: Is It the Same?

P1.01-108 Management of Anlotinib-Related Adverse Events: Data From ALTER 0303

P2.01-01 the Impact of Anlotinib on Brain Metastases of NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)

JCSE01.21 Different Responses to Osimertinib in Primary and Acquired EGFR T790m-Mutant NSCLC Patients

P1.01-107 the Impact of Anlotinib on Quality of Life in Patients With Advance NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)

P3.13-09 ALTER-0303 Study: Tumor Mutation Index (TMI) for Clinical Response to Anlotinib in Advanced NSCLC Patients at 3rd Line

P1.01-30 Crizotinib in Advanced Non-Adenocarcinoma, NSCLC (NA-NSCLC) Patients With ALK Rearrangement: A Retrospective Study and Literature Review

P1.11-19 Expression of TNFRII in Serum Is Correlated With the Significant Risk of Subcentimeter Lung Adenocarcinoma

P2.03-22 OCT4andSOX2 Specific CTLs Plus PD-1 Inhibitor Had Synergistic Effect on Killing CSC and Treating Drug-Resistant Lung Cancer Mice

JCSE01.19 ALTER-0303 Study: Tumor Mutation Index (TMI) for Clinical Response to Anlotinib in Advanced NSCLC Patients at 3rd Line